Who Paid My Doc
Tuan Tran
General Practice Milpitas, CA Doctor of Osteopathy
NPI 1366467102 CMS profile 943234
629 S. Main St., Milpitas, CA 95035
General payments
$380
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tuan Tran of Milpitas, CA is reported in the CMS Open Payments database as having received $380 across 25 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 63rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $58 | 2 | |
| 2021 | General | $127 | 1 | |
| 2019 | General | $195 | 22 |
Beside peers
- Tuan Tran
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Tuan Tran were reported at $58. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Tuan Tran | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $195 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $127 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $58 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 92 drugsPart D claims
5,350
Drug cost
$311,605
Branded share of claims
13.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 107 | $114,146 | |
| Januvia Sitagliptin Phosphate | Brand | 51 | $38,232 | |
| Vascepa Icosapent Ethyl | Brand | 65 | $28,368 | |
| Tradjenta Linagliptin | Brand | 41 | $28,073 | |
| Restasis Cyclosporine | Brand | 14 | $13,033 | |
| Zenpep Lipase/Protease/Amylase | Brand | 13 | $6,744 | |
| Icosapent Ethyl | Generic | 34 | $6,361 | |
| Losartan Potassium | Generic | 458 | $5,677 | |
| Omega-3 Acid Ethyl Esters | Generic | 81 | $3,828 | |
| Atorvastatin Calcium | Generic | 342 | $3,788 |
The 10 drugs with the highest cost, of 92 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$204,882
Medicare patients
82
Services billed
3,493
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Alzheimer's or dementia | 56% | |
| Depression | 48% | |
| Diabetes | 41% | |
| Chronic kidney disease | 39% | |
| Heart failure | 32% | |
| Arthritis | 26% | |
| Ischemic heart disease | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
25 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in California
Related records
General Practice in California
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.